NCT05815628 (NEXUS) is a clinical trial of DISQVER in Febrile Neutropenia, sponsored by Boris Böll.

Who is sponsoring NCT05815628?

NCT05815628 is sponsored by Boris Böll.

What drugs are being tested in NCT05815628?

Interventions in NCT05815628: DISQVER.

What condition does NCT05815628 study?

NCT05815628 studies Febrile Neutropenia.

Is NCT05815628 still recruiting?

NCT05815628 is currently recruiting now. Last updated 8 August 2025.

Last reviewed 2025-08-08 · How we verify

NCT05815628: NEXUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Next-Generation-Sequencing Approach to Neutropenic Sepsis

Recruiting now Last updated 8 August 2025

What this trial tests

trial testing DISQVER in Febrile Neutropenia in 400 participants. Currently enrolling.

Timeline

5 June 2024

Primary endpoint
30 September 2026

1 November 2026

Quick facts

Lead sponsor	Boris Böll
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	400
Start date	5 June 2024
Primary completion	30 September 2026
Estimated completion	1 November 2026
Sites	6 locations across Germany

Drugs / interventions tested

DISQVER

Conditions studied

Febrile Neutropenia — all drugs for Febrile Neutropenia →

Sponsor

Boris Böll

Who can join

18 and older, any sex, with Febrile Neutropenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this prospective, observational, non-interventional, multi-centre study of the diagnostic use of DISQVER in neutropenic patients with FN is to provide further evidence of the efficacy of an NGS-based approach for detecting bloodstream infection in neutropenic patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

[Management of side effects of CAR T cells].
Bach F, Grans-Seibel J, Garcia-Borrega J, Böll B. · · 2025 · PMID 40643658 · DOI 10.1007/s00108-025-01944-y

Verify or expand the search:

Other recruiting trials for Febrile Neutropenia

Currently open trials in the same condition.

NCT07204522 — Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients. · recruiting
NCT06787326 — Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With F · active not recruiting
NCT05786495 — Short Antibiotic Treatment in High Risk Febrile Neutropenia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05815628 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boris Böll
Last refreshed: 8 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05815628.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing